Comparison of device-specific adverse event profiles between Impella platforms

Area of Science:

• Cardiology
• Medical Devices
• Mechanical Circulatory Support

Background:

• The Impella (Abiomed) system offers temporary mechanical circulatory support (MCS) for cardiogenic shock and high-risk revascularization.
• Key devices include the percutaneously implanted Impella CP and surgically implanted Impella 5.0/LD.
• Limited data exists comparing adverse outcomes between Impella CP and 5.0/LD.

Purpose of the Study:

• To compare the clinical outcomes and in-hospital complications of Impella CP versus Impella 5.0/LD.
• To assess device-specific adverse profiles for temporary MCS exceeding 24 hours.

Main Methods:

• Retrospective analysis of 91 consecutive patients receiving Impella support for at least 24 hours (January 2015 - December 2019).
• Patients were stratified based on initial Impella CP or 5.0/LD implantation.
• Clinical outcomes and complications were compared between the two device groups.

Main Results:

• Impella 5.0/LD showed greater device position stability (p=.033) and less hemolysis (p<.001) compared to Impella CP.
• Fewer patients with Impella 5.0/LD required additional MCS (p=.001).
• Impella 5.0/LD patients had higher survival rates from Impella support and to discharge.

Conclusions:

• The Impella 5.0/LD may offer a more favorable device-specific adverse profile for temporary MCS lasting over 24 hours.
• Findings suggest Impella 5.0/LD may be preferable for longer-term temporary MCS.
• Further research is warranted to confirm these comparative outcomes.